PD-L1 status, widely used as a qualification marker for PD-1 blockade therapy, indicated that patients with more than 50% PD-L1 expression in tumor tissue had higher survival chances than those with PD-L1 expression that was less than 50% (Figure 4B, Table 3). Here, PDCD1 is linked to neoplasm.